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of patients at the basal and final visits respectively. 93% (n240) of patients re-
ceived chemotherapy in first line and 78.2% received targeted therapies (mainly
erlotinib) as second line therapies. Twenty-six percent of patients demonstrated
disease progression at the final visit but FACT-L scores showed no difference be-
tween visits; 48.8% of patients reported unchanged perceived health status and
28.1% reported an improvement. Patient and physician LCSS scores showed 86.4%
of patients reported more symptoms than their physician but that there were no
differences between visits. The impact of symptoms on daily life was slightly lower
at the final than the basal visit. Statistically significant differences were observed
between disease progression and the impact of cough (p  0.040) and pain (p 
0.02), and also between the LCSS scale score (p0.01).CONCLUSIONS: Stability and
improvement of some symptoms corresponded to lower impact of the same symp-
toms on patients. The number and type of symptoms were related to HRQoL and
the degree to which patient daily life was affected.
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OBJECTIVES: The aim of our research was to determine the degree of knowledge
concerning cervical cancer screening and human papilloma virus (HPV) and to find
out what information sources would be accepted gladly for these. METHODS: Re-
search was based on quantitative cross-sectional study. Interview was made be-
tween students, workers from health and other sectors, between 15-55 years, from
a South-Transdanubian region. A self-designed questionnaire was used. Analysis
was made by Chi square test, data processing by Microsoft Excel and SPSS 19.0.
RESULTS: Out of 200 people 150 women and 50 men answered the questionnaire.
The number of women participating in gynecological screening was relatively high
(66.7%). 98-81% of the interviewed population knew the meaning of HPV. In addi-
tion, 98% of women with health knowledge as well as 74% of the laywomen knew
the connection between HPV and cervical cancer. 80% of qualified women and 49%
of laywomen knew the screening method. There was a significant difference be-
tween the two groups concerning the meaning of P3 category. 94% of female re-
spondents and 58% of all men have heard of HPV, 68% of them had some knowledge
about the connection between HPV and cervical cancer. However, only 14% of male
knew that HPV could infect both sexes. 66.5% of the respondents show interest in
HPV and/or cervical cancer and 75.5% of them are only partially satisfied with the
information provided. CONCLUSIONS: In summary, it is necessary to provide
proper informative programs. There would be a great chance for citizens to receive
enough information with comprehensive collaboration.
PCN140
RURAL - URBAN DIFFERENCES IN FATALISTIC BELIEFS ABOUT CANCER
PREVENTION
Mehta HB, Johnson ML
University of Houston, Houston, TX, USA
OBJECTIVES: Prior literature showed that people holding fatalistic beliefs, defined
as events are controlled by external forces and humans are powerless to influence
them, are less likely to engage in cancer preventive behavior such as smoking and
exercising. The study aimed to assess rural-urban difference in fatalistic beliefs
about cancer prevention. METHODS: The Health Information National Trend Sur-
vey (HINTS)–2007 data was used in this study; it is conducted biennially by National
Cancer Institute to collect cancer related information from non-institutionalized
adult population. Three fatalistic beliefs were captured in the database: 1) it seems
like everything causes cancer; 2) there are so many different recommendations
about preventing cancer, it is hard to know which ones to follow; and 3) there is not
much you can do to lower your chances of getting cancer. All survey participants
were included in the cohort. Multivariable logistic regression was used to assess
rural-urban differences in three fatalistic beliefs adjusting for age, gender, race,
region, education, employment status, income, health insurance, marital status,
cancer history and cancer seeking information. All analyses were carried out using
jackknife weights to account for survey design enabling us to extrapolate results at
national level. RESULTS: Of 7674 participants, 54.59% agreed that everything
causes cancer, 76.7% agreed that it’s hard to know which recommendations to
follow and 28.29% agreed that they cannot do much to lower chances of getting
cancer. Compared to urban residents, rural residents were 35% (OR: 1.35; 95% CI:
1.12-1.60), 36% (OR: 1.36; 95% CI: 1.10-1.68) and 31% (OR: 1.31; 95% CI: 1.07-1.60) more
likely to hold fatalistic beliefs (i), (ii) and (iii), respectively. CONCLUSIONS: A sub-
stantial proportion of Americans hold fatalistic beliefs about cancer prevention.
Programs or interventions should be specifically designed for rural population to
reduce fatalistic beliefs that might improve cancer prevention behaviors.
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OBJECTIVES: Health status, burden of illness and quality of life are considered
crucial for clinical decision making in lung cancer. The purpose of this study was to
provide the statistical results associated with the patient-reported outcome end-
points at the conclusion of this Phase 3, randomized, open-label, multinational
study of Amrubicin compared with Topotecan.METHODS: Change in quality of life
from Cycle 1 to end-of-study focused on change in lung cancer symptom and
domain scores as well as minimally clinical important difference (MCID) as mea-
sured by the 9-item Lung Cancer Symptom Scale. Longitudinal Mixed Models were
conducted adjusting for Treatment, Disease Stage, Previous Treatment Response,
and Time to Drop Out. MCID was calculated as 1 standard error of measurement
from baseline to end of study. Additionally, change in individual symptom scores
on the LCSS for appetite, cough, dyspnea, fatigue, heomptysis, and pain were eval-
uated descriptively. RESULTS: A total of 607 patients were included in the study at
baseline. Follow-up LCSS data was available on 51.7% of Amrubicin and 46.2% of
Topotecan patients. Amrubicin showed greater clinical improvements on LCSS
total score and symptom burden as measured by the MCID analysis as well as the
longitudinal analysis. Specifically, 65% of patients on Amrubicin improved or dem-
onstrated no change on the LCSS Symptom Burden Score compared to 52% of
Topotecan patients. On the same scale, 30.25% of Topotecan patients worsened
compared to 20.24% of Amrubicin patients (MCID8.17; Chi-Square  6.70, p 
0.0822). CONCLUSIONS: Amrubicin has better symptom control (and QOL vs. To-
potecan) on all symptoms (equivalence on hemoptysis). Subgroup analyses are
consistent and are all in favor of Amrubicin (survival, previous response, disease
stage, and study response). Refractory patients later treated with Amrubicin have
greater symptom control and QoL vs. Topotecan.
PCN142
METHODOLOGICAL LIMITATIONS OF PATIENT-REPORTED OUTCOME
MEASURES (PROMS) IN ONCOLOGY: A META-REVIEW
Smith AB1, Taylor M1, Parry D2
1York Health Economics Consortium, York, North Yorkshire, UK, 2AstraZeneca, Macclesfield, UK
OBJECTIVES: The US Food and Drug Administration (FDA) published guidance
(2006, 2009) on the use of patient-reported outcome measures (PROMs) in labelling
claims places an emphasis on areas such as psychometric validation and interpret-
ability of PROMs, in addition to statistical issues. Given that the vast majority of
oncology PROMs were developed prior to the guidance it is appropriate to re-eval-
uate these PROMs to determine whether they comply with the new regulatory
advice. METHODS: A comprehensive meta-review was undertaken of systematic
reviews of oncology patient-reported outcome measures (PROMs) used in ran-
domised controlled trials (RCTs). The Cochrane Library, PubMed, Ovid, PsychInfo
and EMBASE databases were searched. English language articles published be-
tween 2000 and 2011 were identified. RESULTS: A final 7 systematic reviews were
identified from 435 potential articles involving 443 RCTs in oncology. The reviews
covered lung, breast and colorectal and advanced cancers, leukaemia and multiple
myeloma. A total of 71,379 patients had completed the PROMs in the RCTs. The
most commonly used instruments were the European Organization for Research
and Treatment of Cancer (EORTC) QLQ-C30 (38% of RCTs) and the Functional As-
sessment of Cancer Therapy – General (FACT-G) questionnaire (18% RCTs). A total
of 82% RCTs had used psychometrically validated instruments; 70% trials reported
culturally valid instruments and virtually all RCTs reported timing of PROMs as-
sessment (97%). However, only 28% RCTS reported clinical significance, 32% re-
ported missing data and 25% provided a priori hypothesis of expected changes in
PROMs scores. CONCLUSIONS: Although oncology PROMs currently utilised in
RCTs are compliant with certain areas of the FDA guidance, there are critical as-
pects where these fall short of the requirements, particularly in terms of missing
data and clinical interpretation. These methodological limitations will need to be
addressed if oncology PROMs are to be used to successfully support labelling
claims.
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OBJECTIVES: Testicular cancer (TC) is the most common cancer in young men and
its incidence is increasing. The low mortality rate makes quality of life (QOL) an
important issue in this patient group. Thus, this study aimed at monitoring QOL,
and patient-reported physical and psychosocial symptoms. METHODS: Patients
with TC treated at the urological outpatient unit of Innsbruck Medical University
were consecutively included in the study. QOL assessment was done with the
generic EORTC QLQ-C30 questionnaire and recently also with the TC-specific
EORTC QLQ-TC26 (scale range 0-100). For electronic data capture and result pre-
sentation to physicians we used a software tool called Computer-based Health
Evaluation System (CHES). RESULTS: Since January 2008, we included 408 patients
in the electronic patient-reported outcome monitoring with a total of 1087 symp-
tom assessments. Mean patient age was 43.3 years (SD 11.9). To optimize patient
recruitment and data quality a person was needed for approaching patients ac-
tively and to provide support in case of any questions arising. Collected symptom
data enables longitudinal tracking of symptoms and screening for symptoms that
patients do not volunteer within the patient-physician contact. Overall, most pro-
nounced TC-specific symptoms were negative future perspective (mean 58.1), re-
duced sexual activity (mean 60.2), and impaired sexual enjoyment (mean 69.7).
CONCLUSIONS: Patient-reported outcome monitoring was found to be feasible in
the busy setting of an urologic outpatient unit. As TC patients are of younger age
than most other cancer patient groups, electronic data collection is particularly
feasible, given the high computer literacy in these patients. The software CHES
used for electronic data capture was found to provide high user friendliness for
patients as well as physicians. The data base created within this study allows
comprehensive analyses for a range of research questions
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